Collaboration and License Agreements - Narrative (Details) - USD ($)		1 Months Ended		12 Months Ended
	Dec. 26, 2020	Dec. 31, 2020	Apr. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions						$ 146,384,000
Cost share advance						121,862,000	$ 0
Amounts due to collaboration partner						1,954,000	0
Contract assets						0	0
Deferred revenue						457,933,000	40,000,000	$ 0
Collaboration revenue						22,354,000	0
Cost share advance from collaboration partner						121,227,000	0	0
Shared costs						25,157,000
Richter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received included in current deferred revenue							40,000,000.0
Maximum payment from regulatory milestones achieved									$ 40,000,000.0
Increase in contract liability from regulatory milestones achieved			$ 10,000,000.0			10,000,000.0
Maximum payment from sales-related milestones achieved									$ 107,500,000
Decrease in contract liability from regulatory milestones achieved						33,300,000	$ 0	$ 0
Deferred revenue recognized						33,300,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment from regulatory milestones achieved	$ 100,000,000.0
Increase in contract liability from regulatory milestones achieved						503,600,000
Maximum payment from sales-related milestones achieved	$ 3,500,000,000
Percentage of revenue recognized	100.00%
Upfront payment received		$ 650,000,000.0
Maximum payment from milestones achieved	$ 3,700,000,000
Maximum aggregate payment from milestones achieved	200,000,000.0
Option exercise fee	$ 50,000,000.0
Percent of costs covered by counterparty	100.00%
Additions	$ 150,000,000.0
Repayment period	2 years
Reduction in cost share advance from implied financing costs	$ 3,600,000
Cost share advance	$ 146,400,000
Deferred revenue		$ 503,600,000
Deferred revenue, recognition period	6 years
Amounts due to collaboration partner						1,900,000
Amounts due to collaboration partner, share of profits						$ 1,800,000
Percentage of revenue recognized by counterparty						50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses						$ 100,000
Collaboration revenue						22,400,000
Cost share advance from collaboration partner						121,900,000
Shared costs						25,200,000
Amortized deferred financing costs						$ 600,000
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company				$ 50,000,000.0	$ 100,000,000.0